Sims Portex 1st Response
This article was originally published in The Gray Sheet
Failure of a user to adjust the positive end expiratory pressure (PEEP) valve on the manual resuscitator was the cause of a single reported injury in November 2002 that led to a voluntary Class I recall, the firm says. Corrective actions taken include packaging new PEEP valves separately at the lowest setting (5 cmH2O), instead of attached to the resuscitator at the highest setting (20 cmH2O). A high PEEP valve setting can leave residual air in the lungs, according to the company. Cleared via 510(k) in February 2002, about 10,000 units were distributed prior to the recall, FDA states. A replacement or credit was offered by the firm for returned units. However, Sims Portex, which leads the U.S. manual resuscitation market with a 37% share, says the recall will have a non-significant financial impact...
You may also be interested in...
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.